Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Fingolimod Capsules (0.5mg)
ELC GROUP S.r.o. Czech Republic flag Czech Republic
Abstract ID:
Fingolimod is a generic form of branded drug Gilenya®. It is an immunomodulating drug, mostly used for treating multiple sclerosis (MS). It has been known to reduce the rate of relapses in relapsing-remitting multiple sclerosis....
Contact Rishi Jacob
Participants
You
Email me a copy of this message

Fingolimod received FDA approval on September 21, 2010, and it became the first oral disease-modifying drug approved by the Food and Drug Administration to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis. Novartis announced on March 10, 2011 that it had received a notice of compliance from Health Canada and that the drug would be available April 1, 2011 at pharmacies. On March 17, 2011, the European Medicines Agency approved the drug for use in the European Union. The reference drug Gilenya® belongs to Novartis and had a global sales totalling $2.77 billion in 2015.

Type of Business Relationship Sought
Out Licensing
FEATURED
Last Updated Jul 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
CORPORATION